AJU IB INVESTMENT U.S.
Aju IB Investment U.S. represents the U.S. operations of Aju IB Investment, a leading venture investment firm headquartered in Seoul, Korea with approximately USD $1 billion in capital under management. Based in Boston, Massachusetts, Aju IB Investment U.S. extends Aju IB Investment’s 40-year investment expertise in Asia to the U.S.
Aju IB Investment invests capital from two funds in the US. The first is the Aju IB Life Sciences Overseas Expansion Platform Fund (or the ‘Platform Fund’), which is a landmark US initiative by Aju IB Investment and Korea Development Bank (KDB) and represents the first US fund for both. Closed in 2013, the Platform Fund has approximately USD $60 million in capital funded 50/50 by Aju IB Investment and KDB. The second fund is the Aju Growth & Healthcare Fund, which has approximately USD $40 million in capital.
Aju IB Investment U.S. supports and invests in transformative life sciences products and technologies that improve the lives of patients.
- • Therapeutics serving large unmet medical need
- • Near term value creation
- • Enabling platform technologies with maturing lead candidate
- • Capital efficiency
- • Potential for partnership or alliance with Korean pharmaceutical companies
- • Other areas of interest are medical devices & diagnostics
- • Strong management teams
Primary Investment Criteria:
Our investment process incorporates deep assessment of management, technology and future positioning relative to U.S. and global healthcare markets. Our team has extensive internal and external investment, scientific and operational experience that it applies to its investment process.